NCT02863718View on ClinicalTrials.gov

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

PHASE3CompletedINTERVENTIONAL

Enrollment

515

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 7, 2019

Study Completion Date

July 11, 2022

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Ibrutinib

Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily

DRUG

Placebo

Placebo 420mg daily

Trial Locations (1)

50935

German CLL Study Group, Cologne

All Listed Sponsors

collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

German CLL Study Group

OTHER

NCT02863718 - Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression | Biotech Hunter | Biotech Hunter